Document Detail

Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
MedLine Citation:
PMID:  17097190     Owner:  NLM     Status:  MEDLINE    
Nucleic acids have gained a lot of interest for the treatment of ocular diseases. The first to enter in clinic has been Vitravene an antisense oligonucleotide for the treatment of cytomegalovirus (CMV) infection and more recently, research on aptamers have led to the marketing of anti-vascular endothelial growth factor (VEGF) inhibitor (Macugen) for the treatment of age-related macular degeneration (AMD). The siRNAs appear very promising as they are very potent inhibitors of protein expression. Despite their potential, nucleic acids therapeutic targets of nucleic acid-based drugs are mainly located in the posterior segment of the eye requiring invasive administration which can be harmful if repeated. Their intracellular penetration in some cases needs to be enhanced. This is the reason why adequate delivery systems were designed either to insure cellular penetration, protection against degradation or to allow long-term delivery. A combination of both effects was also developed for an implantable system. In conclusion, the intraocular administration of nucleic acids offers interesting perspectives for the treatment of ocular diseases.
Elias Fattal; Amélie Bochot
Publication Detail:
Type:  Journal Article; Review     Date:  2006-09-15
Journal Detail:
Title:  Advanced drug delivery reviews     Volume:  58     ISSN:  0169-409X     ISO Abbreviation:  Adv. Drug Deliv. Rev.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-11-27     Completed Date:  2007-02-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710523     Medline TA:  Adv Drug Deliv Rev     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1203-23     Citation Subset:  IM    
UMR CNRS 8612, School of Pharmacy, Université Paris Sud, Châtenay-Malabry, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aptamers, Nucleotide / administration & dosage*,  metabolism
Drug Delivery Systems*
Eye Diseases / drug therapy*,  metabolism
Oligonucleotides, Antisense / administration & dosage*,  metabolism
RNA, Small Interfering / administration & dosage*,  metabolism
Reg. No./Substance:
0/Aptamers, Nucleotide; 0/Oligonucleotides, Antisense; 0/RNA, Small Interfering

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mathematical modeling and simulation of drug release from microspheres: Implications to drug deliver...
Next Document:  Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.